Silo pharma's spc-15 awarded u.s. patent protecting ongoing r&d of therapeutic for stress-induced affective disorder and alzheimer's disease

Englewood cliffs, nj, may 09, 2023 (globe newswire) -- silo pharma, inc.  (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the u.s. patent and trademark office (uspto) has issued u.s. patent 11,622,948 titled “biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders.” the new patent claims cover the use of biomarkers in determining the efficacy of the company's portfolio drug spc-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.
SILO Ratings Summary
SILO Quant Ranking